Eivind Smeland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eivind Smeland has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Karsten Kilvaer
Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway
7 shared publications - Lill-Tove Busund
Institute of Medical Biology, University of Tromso, Tromso, Norway
6 shared publications - Roy M. Bremnes
Department of Oncology, University Hospital of North Norway, Tromso, Norway
6 shared publications - Sveinung Wergeland Sørbye
Department of Clinical Pathology, University Hospital of North Norway, 9038 Tromsø, Norway
6 shared publications - Tom Donnem
Department of Oncology, University Hospital of North Norway, N-9038 Tromso, Norway
6 shared publications - Andrej Valkov
Institute of Medical Biology, University of Tromso, Tromso, Norway
3 shared publications
Latest Publications
- Open Access
- 20 January 2014
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 14 (1) , 5
The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk
- 20 January 2014
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 14 (1) , 5
Open AccessThe VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk
- Open Access
- 15 March 2013
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 13 (1) , 9
Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
S-phase kinase-associated protein 2 (Skp2) is a member of mammalian F-box proteins. The purpose of this study is to clarify the prognostic significance of expression of Skp2 related to gender, estrogen receptor (ER) and progesterone receptor (PGR) in soft tissue sarcomas (STS). Skp2 has been demonstrated to display an oncogenic function since its overexpression has been observed in many human cancers. Optimized treatment of STS requires better identification of high-risk patients who will benefit from adjuvant therapy. The prognostic significance of Skp2 related to ER and PGR in STS has not been sufficiently investigated.
- 15 March 2013
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 13 (1) , 9
Open AccessPrognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
S-phase kinase-associated protein 2 (Skp2) is a member of mammalian F-box proteins. The purpose of this study is to clarify the prognostic significance of expression of Skp2 related to gender, estrogen receptor (ER) and progesterone receptor (PGR) in soft tissue sarcomas (STS). Skp2 has been demonstrated to display an oncogenic function since its overexpression has been observed in many human cancers. Optimized treatment of STS requires better identification of high-risk patients who will benefit from adjuvant therapy. The prognostic significance of Skp2 related to ER and PGR in STS has not been sufficiently investigated.
- Open Access
- 3 May 2012
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 12 (1) , 7
Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas
Prognostic markers in curable STS may have the potential to guide therapy after surgical resection. The purpose of this study was to clarify the prognostic impact of the presence of cells and growth factors belonging to the innate immune system in soft tissue sarcomas (STS). The significance of macrophages (CD68), their growth factor macrophage colony-stimulating factor (M-CSF), its receptor colony-stimulating factor-1 receptor (CSF-1R), natural killer cells (CD57) and the general immunomodulating molecule (TGF-beta) are all controversial in STS. Herein, these markers are evaluated and compared to the cell proliferation marker Ki67.
- 3 May 2012
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 12 (1) , 7
Open AccessPrognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas
Prognostic markers in curable STS may have the potential to guide therapy after surgical resection. The purpose of this study was to clarify the prognostic impact of the presence of cells and growth factors belonging to the innate immune system in soft tissue sarcomas (STS). The significance of macrophages (CD68), their growth factor macrophage colony-stimulating factor (M-CSF), its receptor colony-stimulating factor-1 receptor (CSF-1R), natural killer cells (CD57) and the general immunomodulating molecule (TGF-beta) are all controversial in STS. Herein, these markers are evaluated and compared to the cell proliferation marker Ki67.
- Open Access
- 29 February 2012
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 12 (1) , 5
Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas
The purpose of this study was to clarify the prognostic significance of peritumoral lymphocyte infiltration in the capsule of soft tissue sarcomas (STS). Multiple observations in preclinical and clinical studies have shown that the immune system has a role in controlling tumor growth and progression. Prognostic markers in potentially curable STS should guide therapy after surgical resection. The immune status at the time of resection may be important, but the prognostic significance of peritumoral lymphocytes is unknown.
- 29 February 2012
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 12 (1) , 5
Open AccessPrognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas
The purpose of this study was to clarify the prognostic significance of peritumoral lymphocyte infiltration in the capsule of soft tissue sarcomas (STS). Multiple observations in preclinical and clinical studies have shown that the immune system has a role in controlling tumor growth and progression. Prognostic markers in potentially curable STS should guide therapy after surgical resection. The immune status at the time of resection may be important, but the prognostic significance of peritumoral lymphocytes is unknown.
- Open Access
Prognostic Impacts of Hypoxic Markers in Soft Tissue Sarcoma
Background.We aimed to explore the prognostic impact of the hypoxia-induced factors (HIFαs) 1 and 2, the metabolic HIF-regulated glucose transporter GLUT-1, and carbonic anhydrase IX (CAIX) in non-gastrointestinal stromal tumor soft tissue sarcomas (non-GIST STS).Methods.Duplicate cores with viable tumor tissue from 206 patients with non-GIST STS were obtained and tissue microarrays were constructed. Immunohistochemistry (IHC) was used to evaluate expression of hypoxic markers.Results.In univariate analyses, GLUT-1 () and HIF-2α () expression correlated significantly with a poor disease-specific survival (DSS). In the multivariate analysis, however, only high expression of GLUT-1 (HR 1.7, CI 95% 1.1–2.7,) was a significant independent prognostic indicator of poor DSS.Conclusion.GLUT-1 is a significant independent negative prognostic factor in non-GIST STS.Open AccessPrognostic Impacts of Hypoxic Markers in Soft Tissue Sarcoma
Background.We aimed to explore the prognostic impact of the hypoxia-induced factors (HIFαs) 1 and 2, the metabolic HIF-regulated glucose transporter GLUT-1, and carbonic anhydrase IX (CAIX) in non-gastrointestinal stromal tumor soft tissue sarcomas (non-GIST STS).Methods.Duplicate cores with viable tumor tissue from 206 patients with non-GIST STS were obtained and tissue microarrays were constructed. Immunohistochemistry (IHC) was used to evaluate expression of hypoxic markers.Results.In univariate analyses, GLUT-1 () and HIF-2α () expression correlated significantly with a poor disease-specific survival (DSS). In the multivariate analysis, however, only high expression of GLUT-1 (HR 1.7, CI 95% 1.1–2.7,) was a significant independent prognostic indicator of poor DSS.Conclusion.GLUT-1 is a significant independent negative prognostic factor in non-GIST STS. - Open Access
- 22 November 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 200
The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas
The PI3K/Akt pathway is involved in cellular survival pathways by inhibiting apoptotic processes and stimulating cell growth and proliferation. Its negative prognostic value has been proven in many types of cancer. In soft tissue sarcomas, the expression profiles of the PI3K/Akt pathway components are poorly defined and their significance uncertain. We aimed to investigate the prognostic impact of Akt (Akt1) phosphorylated at threonine308 and serine473, Akt2, Akt3, PI3K and PTEN, alone and in coexpression with ER and PgR in non-gastrointestinal stromal tumor soft tissue sarcomas (non-GIST STSs).
- 22 November 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 200
Open AccessThe prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas
The PI3K/Akt pathway is involved in cellular survival pathways by inhibiting apoptotic processes and stimulating cell growth and proliferation. Its negative prognostic value has been proven in many types of cancer. In soft tissue sarcomas, the expression profiles of the PI3K/Akt pathway components are poorly defined and their significance uncertain. We aimed to investigate the prognostic impact of Akt (Akt1) phosphorylated at threonine308 and serine473, Akt2, Akt3, PI3K and PTEN, alone and in coexpression with ER and PgR in non-gastrointestinal stromal tumor soft tissue sarcomas (non-GIST STSs).
- Open Access
- 6 July 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 104
Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients
Non-gastrointestinal stromal tumor soft-tissue sarcomas (non-GIST STSs) constitute a heterogeneous group of tumors with poor prognosis. Fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor-1 (FGFR-1), in close interplay with platelet-derived growth factor-B (PDGF-B) and vascular endothelial growth factor receptor-3 (VEGFR-3), are strongly involved in angiogenesis. This study investigates the prognostic impact of FGF2 and FGFR-1 and explores the impact of their co-expression with PDGF-B and VEGFR-3 in widely resected tumors from non-GIST STS patients.
- 6 July 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 104
Open AccessFibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients
Non-gastrointestinal stromal tumor soft-tissue sarcomas (non-GIST STSs) constitute a heterogeneous group of tumors with poor prognosis. Fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor-1 (FGFR-1), in close interplay with platelet-derived growth factor-B (PDGF-B) and vascular endothelial growth factor receptor-3 (VEGFR-3), are strongly involved in angiogenesis. This study investigates the prognostic impact of FGF2 and FGFR-1 and explores the impact of their co-expression with PDGF-B and VEGFR-3 in widely resected tumors from non-GIST STS patients.